Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiationJoseph Panoff, Jean L. Wright, Judith Hurley et al.|Breast Cancer Research and Treatment|2011Cited by 88
Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapyJean L. Wright, Judith Hurley, Cristiane Takita et al.|The Breast|2011Cited by 20
Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2− Breast CancerJean L. Wright, Judith Hurley, Kunal Saigal et al.|American Journal of Clinical Oncology|2015Cited by 11
Pathologic Response and Locoregional Outcome in Post-menopausal ER Positive Breast Cancer Patients Receiving Neoadjuvant Endocrine Therapy vs. Cytotoxic ChemotherapyKunal Saigal, Jean L. Wright, Asif Saeed et al.|International Journal of Radiation Oncology*Biology*Physics|2011Cited by 2
Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers.T. Ambros, Judith Hurley, Victoria Sujoy et al.|Journal of Clinical Oncology|2011Cited by 1